Study points to potential reversal of rare childhood neurological disorder by reactivating silenced copy of the disease-linked gene
Jan. 30, 2017
| By Rachel Tompa / Fred Hutch News Service
A research team led by Fred Hutch's Dr. Antonio Bedalov have uncovered 30 genes that could, one day, serve as therapeutic targets to reverse Rett syndrome, a rare neurological disorder that affects primarily girls and women. The new findings are described in a study published today in the journal Proceedings of the National Academy of Sciences.
Ignition Award helps to fund projects that show promise for sparking new grant applications or future pre-clinical and clinical studies
March 2, 2009
Dr. Antonio Bedalov of the Fred Hutchinson Cancer Research Center is among the first three recipients of the University of Washington School of Pharmacy’s Ignition Awards. Bedalov will lead a study titled "Identification of Pharmacodynamic Biomarkers for Inhibitors of NAD-dependent Protein Deacetylases Using Mass Spectrometry."
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.